HER2 genetic heterogeneity in breast carcinoma

Journal of Clinical Pathology

Volumn 64, Issue 12, 2011, Pages 1112-1116

  Öhlschlegel, Christian ^a   Zahel, Katharina ^a   Kradolfer, Doris ^a   Hell, Margreth ^a   Jochum, Wolfram ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CENTROMERE; CHROMOSOME 17; COHORT ANALYSIS; CYTOMETRY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE CLUSTER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE CELL ANALYSIS; TUMOR CELL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHROMOSOMES, HUMAN, PAIR 17; DNA PROBES; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENETIC HETEROGENEITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PLOIDIES; RETROSPECTIVE STUDIES;

EID: 81855170189     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200265     Document Type: Article

References (20)

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
2. Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-81. (Pubitemid 41060140)
3. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007;25:5418-25. (Pubitemid 350232218)
4. Barry WT, Kernagis DN, Dressman HK, et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 2010;28:2198-206.
5. Lerma E, Peiro G, Ramon T, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2007;20:1200-7. (Pubitemid 47609069)
6. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer - a rare event. Breast J 2007;13:122-9. (Pubitemid 46280606)
7. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009;131:678-82.
8. Shin SJ, Hyjek E, Early E, et al. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 2006;14:279-84. (Pubitemid 44545764)
9. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 2007;16:207-10. (Pubitemid 350196977)
10. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
11. Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203:918-26. (Pubitemid 39089280)
12. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31.
13. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010;41:914-17.
14. Andersson J, Linderholm B, Bergh J, et al. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 2004;12:14-20. (Pubitemid 38332313)
15. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-12.
16. Klintman M, Bendahl PO, Grabau D, et al. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010;23:251-9.
17. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005;11:4393-9. (Pubitemid 40825629)
18. Auer G, Askensten U, Ahrens O. Cytophotometry. Hum Pathol 1989;20:518-27. (Pubitemid 19164364)
19. Kronenwett U, Huwendiek S, Ostring C, et al. Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res 2004;64:904-9. (Pubitemid 38176891)
20. Glöckner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-26. (Pubitemid 35191545)